# DSIP Peptide Dosage in the Research Literature

> DSIP peptide dosage protocols from published human trials and animal studies — routes of administration, half-life data, timing, and the U-shaped dose-response. Research context only.

## DSIP Peptide Dosage in the Research Literature

DSIP peptide dosage in published research varies substantially by species, route, and study objective. The primary human clinical trial dose is 25 nmol/kg administered intravenously — used in the Bes et al. (1992) matched-pairs insomnia study (n=16) and the Dick et al. (1983, 1984) withdrawal cohorts (n=67 and n=107) [1][15][16]. Animal EEG studies used 120 nmol/kg subcutaneously in cats [13]. Mechanistic GH studies used 5 mcg intracerebroventricularly in rats [7]. The mouse aging and anti-tumor study used approximately 100 mcg/kg subcutaneously for five consecutive days monthly [25].

None of the research protocols for this unapproved research peptide translate to human dosing recommendations.

## DSIP Peptide Dosing Chart: Research Protocol Ranges

| Species | Route | Dose | Duration | Study objective | Citation |
|---|---|---|---|---|---|
| Human | IV | 25 nmol/kg | 3 consecutive nights | Chronic insomnia (n=16) | Bes 1992 [1] |
| Human | IV | Not specified | 7 consecutive nights | Severe chronic insomnia (n=14) | Schneider-Helmert 1987 [3] |
| Human | IV | Not specified | 10 injections | Severe insomnia (n=7) | Kaeser 1984 [4] |
| Human | IV | Not specified | 1 acute dose | Insomnia (n=6) | Schneider-Helmert 1981 [2] |
| Human | IV | 25 nmol/kg | Multiple injections | Opiate/alcohol withdrawal (n=67) | Dick 1983 [15] |
| Human | IV | Multiple | Multiple injections | Withdrawal (n=107) | Dick 1984 [16] |
| Human | IV | 5 days + follow-up | Every 48-72 h | Chronic pain (n=7) | Larbig 1984 [18] |
| Cat | SC | 120 nmol/kg | Single dose | EEG/sleep architecture | Susic 1987 [13] |
| Rat | ICV | 5 mcg | Single dose | GH secretion mechanism | Iyer 1987 [7] |
| Rat | Intranasal | 120 mcg/kg | 8 days | Stroke motor recovery | Tukhovskaya 2021 [28] |
| Mouse | SC | ~100 mcg/kg | 5 days/month | Aging and tumor incidence | Popovich 2003 [25] |

## DSIP half-life and plasma binding

Free DSIP plasma half-life is 2-4 minutes across mammalian species: 4.0 ±0.7 minutes in dogs, 2.9 minutes in monkeys, 2.0 ±0.54 minutes in rats [11]. Despite rapid plasma clearance, in-vivo effects in published studies persist for hours to days. Carrier protein binding and downstream neuroendocrine cascades are the proposed explanations.

## U-shaped dose-response

DSIP demonstrates a parabolic (U-shaped) dose-response: minimal effective dose approximately 10 ng; maximal response at approximately 1 mcg in some assays; higher doses produce diminishing or no effect [23]. Phosphorylated DSIP-P is more potent than the native sequence.

## DSIP Nasal Spray vs. Subcutaneous Injection: Administration Routes

Published human clinical trials have used intravenous administration exclusively. Intranasal DSIP was used in a rat stroke model at 120 mcg/kg over 8 days [28]. CNS penetration data from Banks et al. (1986) showed lipophilicity predicts CSF entry (r = 0.813, p < 0.00005) [12]. No human comparative study across routes has been published.

## References

[1] Bes F et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. Neuropsychobiology. 1992;26(4):193-197. https://pubmed.ncbi.nlm.nih.gov/1299794/
[2] Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP on disturbed human sleep. Experientia. 1981;37(9):913-917. https://pubmed.ncbi.nlm.nih.gov/7028502/
[3] Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. European Neurology. 1987;27(2):120-129. https://pubmed.ncbi.nlm.nih.gov/3622582/
[4] Kaeser HE. A clinical trial with DSIP. European Neurology. 1984;23(5):386-388. https://pubmed.ncbi.nlm.nih.gov/6391926/
[7] Iyer KS, McCann SM. Delta sleep-inducing peptide (DSIP) stimulates GH release in the rat. Peptides. 1987;8(1):45-48. https://pubmed.ncbi.nlm.nih.gov/3575154/
[11] Kato N et al. Development of an enzyme immunoassay for DSIP and determination of metabolic clearance rate. Neuroendocrinology. 1984;38(2):126-130. https://pubmed.ncbi.nlm.nih.gov/6379493/
[12] Banks WA et al. Entry of DSIP peptides into dog CSF. Brain Research Bulletin. 1986;17(2):155-158. https://pubmed.ncbi.nlm.nih.gov/3768731/
[13] Susic V. The effect of subcutaneous DSIP on parameters of sleep in the cat. Physiology and Behavior. 1987;40(5):569-572. https://pubmed.ncbi.nlm.nih.gov/3671519/
[15] Dick P et al. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide. Neuropsychobiology. 1983;10(4):233-237. https://pubmed.ncbi.nlm.nih.gov/6328354/
[16] Dick P et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. European Neurology. 1984;23(5):364-371. https://pubmed.ncbi.nlm.nih.gov/6548969/
[18] Larbig W et al. Therapeutic effects of DSIP in patients with chronic pronounced pain episodes. European Neurology. 1984;23(5):372-385. https://pubmed.ncbi.nlm.nih.gov/6548970/
[23] Schoenenberger GA. Characterization, properties and multivariate functions of DSIP. European Neurology. 1984;23(5):321-345. https://pubmed.ncbi.nlm.nih.gov/6548966/
[25] Popovich IG et al. Effect of Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. Mechanisms of Ageing and Development. 2003;124(6):721-731. https://pubmed.ncbi.nlm.nih.gov/12782416/
[28] Tukhovskaya EA et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. 2021;26(17):5173. https://pubmed.ncbi.nlm.nih.gov/34500605/

---

Nine residues, twenty-five studies, one grid — the DSIP peptide research record indexed by finding, not by vendor.